Evidence map›Paper›PMID 27086483›Full record

ArticleOral oncology2016

Oncolytic adenoviruses targeted to Human Papilloma Virus-positive head and neck squamous cell carcinomas.

Christopher J LaRocca, Joohee Han, Amanda O Salzwedel, Julia Davydova, Mark C Herzberg, Rajaram Gopalakrishnan, Masato Yamamoto

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oral oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Christopher J LaRoccaDepartment of Surgery, University of Minnesota, United States.
Joohee HanDepartment of Surgery, University of Minnesota, United States.
Amanda O SalzwedelDepartment of Surgery, University of Minnesota, United States.
Julia DavydovaDepartment of Surgery, University of Minnesota, United States; Masonic Cancer Center, University of Minnesota, United States.
Mark C HerzbergDepartment of Diagnostic & Biological Sciences, School of Dentistry, University of Minnesota, United States.
Rajaram GopalakrishnanDepartment of Diagnostic & Biological Sciences, School of Dentistry, University of Minnesota, United States.
Masato YamamotoDepartment of Surgery, University of Minnesota, United States; Masonic Cancer Center, University of Minnesota, United States; Institute of Molecular Virology, University of Minnesota, United States. Electronic address: yamam016@umn.edu.
University of Minnesota · US

Funding

TRAINING GRANT IN MICROBIOLOGY/CANCER RESEARCHT32CA009138 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Scott M. Dehm · 1985 to 2026
$11.3M
Systemic Therapy with Infectivity-Selective Oncolytic Adenovirus for PDACR01CA196215 · NCI · UNIVERSITY OF MINNESOTA · PI YAMAMOTO, MASATO · 2016 to 2020
$1.7M
Novel Theranostics for Pancreatic CancerR01CA174861 · NCI · UNIVERSITY OF MINNESOTA · PI DAVYDOVA, JULIA · 2014 to 2018
$1.6M
Next Generation Oncolytic Adenovirus for Advanced Pancreatic Cancer TreatmentR01CA168448 · NCI · UNIVERSITY OF MINNESOTA · PI YAMAMOTO, MASATO · 2013 to 2017
$1.6M
NCI NIH HHS R01 CA168448NCI NIH HHS R01CA168448NCI NIH HHS R01 CA174861NCI NIH HHS R01CA174861NCI NIH HHS R01 CA196215NCI NIH HHS R01CA196215NCI NIH HHS T32 CA009138
6 · The paper itself

Abstract

objectivesIn recent years, the incidence of Human Papilloma Virus (HPV)-positive head and neck squamous cell carcinomas (HNSCC) has markedly increased. Our aim was to design a novel therapeutic agent through the use of conditionally replicative adenoviruses (CRAds) that are targeted to the HPV E6 and E7 oncoproteins.

methodsEach adenovirus included small deletion(s) in the E1a region of the genome (Δ24 or CB016) intended to allow for selective replication in HPV-positive cells. In vitro assays were performed to analyze the transduction efficiency of the vectors and the cell viability following viral infection. Then, the UPCI SCC090 cell line (HPV-positive) was used to establish subcutaneous tumors in the flanks of nude mice. The tumors were then treated with either one dose of the virus or four doses (injected every fourth day).

resultsThe transduction analysis with luciferase-expressing viruses demonstrated that the 5/3 fiber modification maximized virus infectivity. In vitro, both viruses (5/3Δ24 and 5/3CB016) demonstrated profound oncolytic effects. The 5/3CB016 virus was more selective for HPV-positive HNSCC cells, whereas the 5/3Δ24 virus killed HNSCC cells regardless of HPV status. In vivo, single injections of both viruses demonstrated anti-tumor effects for only a few days following viral inoculation. However, after four viral injections, there was statistically significant reductions in tumor growth when compared to the control group (p<0.05).

conclusionCRAds targeted to HPV-positive HNSCCs demonstrated excellent in vitro and in vivo therapeutic effects, and they have the potential to be clinically translated as a novel treatment modality for this emerging disease.

Indexed as

Oncolytic VirotherapyAdenoviridaeAlphapapillomavirusAnimalsCarcinoma, Squamous CellCell Line, TumorGenetic VectorsHead and Neck NeoplasmsHumansInjections, IntralesionalMiceMice, NudeVirus ReplicationHead and neck cancerHuman papillomavirusOncolytic adenovirusSquamous cell carcinoma

Identifiers

PMID27086483
PMCPMC5089835
OpenAlexW2310637600

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.